Researches

South Egypt Cancer Institute

Assiut University

# Title Department Research Member Research Year
11 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Salah Mabrouk Khallaf Abd Rabou 2024
12 Beta Endorphins, Interleukin 1 and Interleukin 38 in Covid Patients Associated with Neuropsychological Manifestations Department of Clinical Pathology Prof. Eman Massad Zaki El-Hefny 2024
13 Assessment of Response to Hormonal Therapy by Serum Ki-67 as a Biomarker in Non-metastatic Hormone Positive Breast Cancer Department of Medical Oncology Zeina Omar Attia Sayed 2024
14 Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study Department of Radiotherapy and Nuclear medicine Dr. Esraa Roshdy Hassan Mohamed 2024
15 Diagnostic efficacy of Ovarian-Adnexal Reporting and Data System (ORADS) in Evaluation of Ovarian Lesions Department of Radiology Dr. Haisam Ahmed Samy Aly Atta 2024
16 Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study Department of Radiotherapy and Nuclear medicine ِAya AbdelBaset Ahmed 2024
17 Role of Irreversible Electroporation in Solid Abdominal Tumors Management Department of Radiology Prof. Amro Farouk ِAhmedMourad 2024
18 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Prof. Ashraf Zeidan Abdalla Ahmed 2024
19 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Dr. Amen Hamdy Zaki Ali 2024
20 Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line Department of Medical Oncology Amany Mohammed Abdel Moatamed 2024